“Illumina Announces Grail Sale: Navigating Antitrust Challenges in Gene Sequencing”
A Gene Sequencing Pioneer Battles Over What It Can Buy, The New York Times Illumina, a leading gene-sequencing machine producer, has announced the sale of Grail, a cancer test developer it acquired for $7.1 …